文献速递中医内科中药与中成药合理使用

十种中药复方治疗慢阻肺急性加重期疗效比较:系统评价与贝叶斯网络荟萃分析

Comparative effectiveness of ten traditional Chinese herbal formulas for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Bayesian network meta-analysis.
PubMed 文献 · Front Pharmacol · 2026-01-15

该研究纳入132项RCT共13177例患者,采用贝叶斯网络荟萃分析比较十种中药复方联合常规治疗对AECOPD的疗效。结果显示十种复方联合常规治疗均优于单用常规治疗,QQHT在改善肺功能方面排名最高,XQL在纠正血气异常方面排名最高,但GRADE证据确定性多为极低。

要点

  • 十种中药复方联合常规治疗在AECOPD中均优于单用常规治疗。
  • 清肺化痰汤在改善肺功能指标上排序最高。
  • 小青龙汤在纠正动脉血气异常上排序最高。

核心结论

  • 基于当前证据,清肺化痰汤和小青龙汤可能是最有前景的中药复方。
  • 但证据确定性低,临床选择应结合患者具体病理生理特征和个体因素综合评估。

研究设计与样本

  • 纳入132项RCT,共13177例AECOPD患者,比较十种中药复方联合常规治疗与常规治疗。
  • 采用RoB 2评估偏倚风险,进行贝叶斯NMA、配对荟萃分析、meta回归、亚组和敏感性分析及发表偏倚分析,采用GRADE分级评估证据确定性。

主要发现

  • 配对荟萃分析和网络荟萃分析均显示十种中药复方联合常规治疗在AECOPD治疗中均优于单用常规治疗。
  • 在改善肺功能(FEV1、FEV1%pred、FEV1/FVC)方面,清肺化痰汤、二陈汤合三子养亲汤和苇茎汤成为最有效干预的概率最高。
  • 在纠正动脉血气异常(PaO2、PaCO2)方面,麻杏石甘汤、小青龙汤和越婢加半夏汤排序最高。
  • GRADE框架评定NMA和大多数PMA结果的证据确定性为「极低」。

关键数值与推荐

  • 纳入132项RCT,涉及13177例参与者。
  • 所有十种中药复方联合常规治疗均优于单用常规治疗。
  • 肺功能改善排序前三:清肺化痰汤、二陈汤合三子养亲汤、苇茎汤。
  • 血气异常纠正排序前三:麻杏石甘汤、小青龙汤、越婢加半夏汤。
  • GRADE证据确定性:NMA和大多数PMA结果为「极低」。

临床怎么用

  • 临床可考虑在常规治疗基础上联合中药复方治疗AECOPD。
  • 改善肺功能可优先考虑清肺化痰汤,纠正血气异常可优先考虑小青龙汤。
  • 最终选方应基于患者具体病理生理特征和个体因素综合评估,不应仅依赖排序结果。
  • 鉴于证据确定性极低,需谨慎解读排序结果并关注进一步研究。

局限性

  • GRADE框架评定NMA和大多数PMA结果的证据确定性为「极低」。
  • 多数现有RCT和荟萃分析仅评估单一中药复方作为常规治疗的附加疗法。
  • 需要进一步高质量的头对头比较研究验证发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditional Chinese medicine (TCM) has emerged as a valuable adjunctive approach for respiratory diseases, with accumulating evidence supporting its efficacy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) management. However, most existing randomized controlled trials (RCTs) and meta-analyses have focused on evaluating single traditional Chinese herbal formulas as an add-on to conventional therapy (CT). The comparative efficacy among these formulas remains uncertain, creating a critical evidence gap that hampers clinical decision-making. Network meta-analysis (NMA) provides a methodological framework to address this limitation by enabling simultaneous comparison of multiple interventions. METHODS: RCTs of these ten herbal formulas in combination with CT for the treatment of AECOPD were searched in five English and four Chinese databases. The search covered the period from the date of database inception to 20 August 2024, with a final update performed on 28 November 2025. The risk of bias of the included RCTs was critically assessed using the Cochrane Risk-of-Bias tool for randomized trials, version 2 (RoB 2). Bayesian NMA, pairwise meta-analysis (PMA), meta-regression, subgroup and sensitivity analyses, and publication bias analysis were carried out. The certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: A total of 132 eligible RCTs involving 13,177 participants were included. Both PMA and NMA demonstrated that all ten herbal formulas combined with CT were more effective than CT alone in treating AECOPD. Based on the ranking results, Qingqihuatan decoction (QQHT), Erchen decoction combined with Sanziyangqin decoction (ECSZYQ), and Weijing decoction (WJ) had the highest probability of being the most efficacious interventions in improving lung function (FEV1, FEV1%pred, FEV1/FVC). For the correction of arterial blood gas abnormalities (PaO2, PaCO2), Maxingshigan decoction (MXSG), Xiaoqinglong decoction (XQL), and Yuebi Jia Banxia decoction (YBBX) were ranked highest. However, the GRADE framework rated the certainty of evidence for NMA and most PMA results as "very low". CONCLUSION: Based on the current evidence, QQHT and XQL appear to be the most promising herbal formulas. Nevertheless, given the low certainty of evidence, caution is warranted in interpreting these findings. The final selection in clinical practice should be guided by a comprehensive assessment of the patient's specific pathophysiological profile and individual factors. Further high-quality, head-to-head comparative studies are needed to validate these findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024622734.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Yu E, Tian C, Jiang P, et al. Comparative effectiveness of ten traditional Chinese herbal formulas for acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Bayesian network meta-analysis. Front Pharmacol. 2026. PMID: 41625332. doi:10.3389/fphar.2025.1585150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。